{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:48:04Z","timestamp":1787237284992,"version":"build-2736575974"},"reference-count":25,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2020,12,22]],"date-time":"2020-12-22T00:00:00Z","timestamp":1608595200000},"content-version":"vor","delay-in-days":21,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100012633","name":"Royal North Shore Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012633","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Internal Medicine Journal"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Guillain\u2013Barr\u00e9 syndrome (GBS) causes acute neuromuscular weakness. Severe cases are life\u2010threatening and many are left disabled. Intravenous immunoglobulin (IVIg) and plasma exchange (PE), along with supportive care, are the mainstays of treatment. Treatment choice is influenced by multiple factors. The clinico\u2010epidemiological features of GBS in Australia have not been reviewed in 30\u2009years and few studies have assessed contemporary treatment choices.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To investigate the clinico\u2010epidemiological features, choice of treatment, clinical course and outcomes of GBS patients in an Australian tertiary metropolitan hospital.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective observational study was performed of GBS presentations to a tertiary hospital in Sydney, Australia, over 5\u2009years. Clinico\u2010epidemiological features, treatment choices, clinical course and outcomes were assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We reviewed 46 GBS patients (54% male), average age 55\u2009years. Antecedent infection was identified in 61%. Twenty\u2010eight per cent had preceding immunogenic events or conditions. Acute inflammatory demyelinating polyradiculoneuropathy was the most common subtype (78%). Cerebrospinal fluid albumino\u2010cytologic dissociation was present in 43%. Electrodiagnostic testing most frequently demonstrated demyelination (64%). Ninety\u2010eight per cent received immunotherapy, mostly IVIg (93%). Twenty\u2010two per cent received further treatment due to treatment\u2010related fluctuations or lack of improvement. Thirteen per cent required ICU admission and 46% needed rehabilitation. There were no deaths or need for mechanical ventilation. Seventy\u2010one per cent of the follow\u2010up cohort had residual disability at 6 months, but this was generally mild.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The clinico\u2010epidemiological features are consistent with previous cohorts. Our experience in a large Australian tertiary centre demonstrates a clear preference for IVIg over PE.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/imj.14705","type":"journal-article","created":{"date-parts":[[2019,11,24]],"date-time":"2019-11-24T09:03:35Z","timestamp":1574586215000},"page":"1500-1504","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Guillain\u2013Barr\u00e9 syndrome: clinical features, treatment choices and outcomes in an Australian cohort"],"prefix":"10.1111","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3497-0959","authenticated-orcid":false,"given":"Stephanie L.","family":"Barnes","sequence":"first","affiliation":[{"name":"Department of Neurology Concord Repatriation General Hospital  Sydney New South Wales Australia"},{"name":"Faculty of Medicine University of Notre Dame  Sydney New South Wales Australia"},{"name":"Department of Neurology Royal North Shore Hospital  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey K.","family":"Herkes","sequence":"additional","affiliation":[{"name":"Department of Neurology Royal North Shore Hospital  Sydney New South Wales Australia"},{"name":"Faculty of Medicine University of Sydney  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,12,22]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1159\/000184748"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2014.121"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awy232"},{"key":"e_1_2_6_5_1","first-page":"CD002063","article-title":"Intravenous immunoglobulin for Guillain\u2010Barr\u00e9 syndrome","author":"Hughes RA","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_6_6_1","first-page":"CD001798","article-title":"Plasma exchange for Guillain\u2010Barr\u00e9 syndrome","author":"Chevret S","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.47.3.674"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-199305000-00006"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(08)70215-1"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007719"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/jns.12286"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30114-5"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/jns.12194"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6963-11-101"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(78)92644-2"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410440512"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.1987.tb120153.x"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1159\/000324710"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001648-199811000-00006"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000000451"},{"key":"e_1_2_6_21_1","first-page":"588","article-title":"Guillain\u2010Barr\u00e9 syndrome, pregnancy, and the puerperium","volume":"9","author":"Mack T","year":"1998","journal-title":"Epidemiology"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2008.156463"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awt285"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/jns.12239"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinph.2012.01.025"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2008.08.033"}],"container-title":["Internal Medicine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/imj.14705","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/imj.14705","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/imj.14705","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T09:23:32Z","timestamp":1693733012000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/imj.14705"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":25,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["10.1111\/imj.14705"],"URL":"https:\/\/doi.org\/10.1111\/imj.14705","archive":["Portico"],"relation":{},"ISSN":["1444-0903","1445-5994"],"issn-type":[{"value":"1444-0903","type":"print"},{"value":"1445-5994","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"2019-08-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-11-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}